Visara, a subsidiary of NovaBridge Biosciences, has obtained an exclusive option to acquire worldwide rights to YOL104-2, a bioengineered therapy under development for ocular surface squamous neoplasia (OSSN), a cancerous eye condition with no FDA-approved treatment. This move aligns with Visara's strategy to expand its ophthalmology portfolio and address significant unmet medical needs. If exercised, the acquisition will involve milestone payments and royalties to YOLO Immune, the current developer. The development of YOL104-2 could offer a novel treatment option for OSSN patients, advancing Visara's position in eye disease therapies.
Visara's acquisition option for YOL104-2 offers context for readers. For those tracking health-sector stocks on Pluang, 80 of 150 US stocks rose and 62 fell as of Oct 20, 2026 17:41 WIB. Notable movers include XRAY at USD 8.84 (+4.99%), ENVB at USD 1.34 (-4.96%) with 100% sell order activity, and MMED at USD 17.17 (-3.49%).
RoyaLand Company Ltd. announced Palazzo Chronicles, a free-to-play mobile match-3 puzzle game set in 19th-century Piedmont during Italy's reunification. Players help Adelaide restore her inherited family castle by solving puzzles and rebuilding rooms...
Route 92 Medical has secured a $100 million senior secured debt facility from Trinity Capital to strengthen its balance sheet and support ongoing product innovation and commercial growth. The funding will help the company expand its neurovascular int...
First Federal Savings Bank marks its 122nd anniversary, highlighting over a century of service to Southwest Indiana and Western Kentucky. The bank has grown from a single community institution to ten locations, focusing on personal service, local dec...
Aclarion, Inc. announced an 85% year-over-year increase in scan volumes for Q3 2026, contributing to a 117% growth for the first nine months of the year. The company highlighted the publication of supportive clinical data in the European Spine Journa...
The global electric vehicle (EV) components market is projected to grow from $486.4 billion in 2026 to $1.28 trillion by 2036, expanding at a 10.2% CAGR. Growth is fueled by rising EV adoption, advancements in battery systems, power electronics, and ...
